BRPI0817223A2 - Inibidores da interação entre mdm2 e p53 - Google Patents

Inibidores da interação entre mdm2 e p53

Info

Publication number: BRPI0817223A2
Authority: BR; Brazil
Prior art keywords: mdm2; interaction inhibitors; inhibitors; interaction
Prior art date: 2007-09-21

Application number

BRPI0817223-4A2A

Other languages

English (en)

Inventor

Virginie Sophie Poncelet

Sophie Coupa

Pierre-Henri Storck

Bruno Schoentjes

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-21

Filing date

2008-09-18

Publication date

2015-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817223(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-18 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2015-03-10 Publication of BRPI0817223A2 publication Critical patent/BRPI0817223A2/pt

2020-04-07 Publication of BRPI0817223B1 publication Critical patent/BRPI0817223B1/pt

2021-05-25 Publication of BRPI0817223B8 publication Critical patent/BRPI0817223B8/pt

Links

102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 1
108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000003993 interaction Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI0817223A 2007-09-21 2008-09-18 inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação BRPI0817223B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07116889		2007-09-21
PCT/EP2008/062433 WO2009037308A1 (en)	2007-09-21	2008-09-18	Inhibitors of the interaction between mdm2 and p53

Publications (3)

Publication Number	Publication Date
BRPI0817223A2 true BRPI0817223A2 (pt)	2015-03-10
BRPI0817223B1 BRPI0817223B1 (pt)	2020-04-07
BRPI0817223B8 BRPI0817223B8 (pt)	2021-05-25

Family

ID=38910911

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817223A BRPI0817223B8 (pt)	2007-09-21	2008-09-18	inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação

Country Status (23)

Country	Link
US (4)	US9573933B2 (pt)
EP (1)	EP2203440B1 (pt)
JP (1)	JP5438007B2 (pt)
CN (2)	CN101868453A (pt)
AR (1)	AR068627A1 (pt)
AT (1)	ATE502934T1 (pt)
AU (1)	AU2008300527B2 (pt)
BR (1)	BRPI0817223B8 (pt)
CA (1)	CA2699849C (pt)
CL (1)	CL2008002798A1 (pt)
DE (1)	DE602008005784D1 (pt)
DK (1)	DK2203440T3 (pt)
ES (1)	ES2363838T3 (pt)
HR (1)	HRP20110394T1 (pt)
JO (1)	JO2704B1 (pt)
MX (1)	MX2010003060A (pt)
PA (1)	PA8796901A1 (pt)
PE (1)	PE20090817A1 (pt)
RU (1)	RU2477724C2 (pt)
SI (1)	SI2203440T1 (pt)
TW (1)	TWI434841B (pt)
UY (1)	UY31349A1 (pt)
WO (1)	WO2009037308A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2704B1 (en)	2007-09-21	2013-03-03	جانسين فارماسوتيكا ان في	Interference inhibition factors between MD2 and B53
US8354444B2 (en) *	2008-09-18	2013-01-15	Hoffmann-La Roche Inc.	Substituted pyrrolidine-2-carboxamides
EA021883B1 (ru)	2009-02-04	2015-09-30	Янссен Фармацевтика Нв	Производные индола в качестве противораковых агентов
TW201139370A (en) *	2009-12-23	2011-11-16	Lundbeck & Co As H	Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) *	2011-06-07	2014-08-13	中国人民解放军第二军医大学	硫代苯二氮卓类化合物及其作为药物的用途
US9073851B2 (en)	2011-10-28	2015-07-07	Board Of Regents, The University Of Texas System	Compositions and methods for treating cancer
ES2410704B1 (es) *	2011-11-28	2014-04-29	Universitat De Barcelona	Indoleninas fluoradas útiles para el tratamiento del cáncer.
WO2014100065A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
CN109152843A (zh)	2016-05-20	2019-01-04	豪夫迈·罗氏有限公司	Protac抗体缀合物及其使用方法
EP3558164B1 (en)	2016-12-21	2024-10-09	TriFlo Cardiovascular Inc.	Heart valve support device and methods for making the same
WO2022183006A1 (en)	2021-02-25	2022-09-01	Mayo Foundation For Medical Education And Research	Compounds for programmable protein degradation and methods of use for the disease treatment
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en)	2023-05-23	2024-11-28	Valerio Therapeutics	Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1734401A (en) *	1999-12-09	2001-06-18	Mitsubishi Pharma Corporation	Carboxyamido derivatives
ES2566056T3 (es) *	2001-03-29	2016-04-08	Eli Lilly And Company	N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US20030149038A1 (en) *	2001-11-09	2003-08-07	The Regents Of The University Of California	Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) *	2004-02-10	2004-02-10	Astrazeneca Ab	Novel compounds
US7540139B2 (en) *	2004-08-16	2009-06-02	Rowse Hydraulic Rakes Co., Inc.	Foldable hay rake
MX2007003375A (es) *	2004-09-22	2007-05-07	Janssen Pharmaceutica Nv	Inhibidores de la interaccion entre mdm2 y p53.
US20060217370A1 (en) *	2005-02-18	2006-09-28	Ethan Burstein	Compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) *	2005-06-24	2009-08-18	Hoffman-La Roche Inc.	Oxindole derivatives
WO2007107543A1 (en) *	2006-03-22	2007-09-27	Janssen Pharmaceutica N.V.	Inhibitors of the interaction between mdm2 and p53
AR067813A1 (es) *	2007-08-06	2009-10-21	Janssen Pharmaceutica Nv	Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
JO2704B1 (en)	2007-09-21	2013-03-03	جانسين فارماسوتيكا ان في	Interference inhibition factors between MD2 and B53

2008
- 2008-09-11 JO JO2008406A patent/JO2704B1/en active
- 2008-09-17 CL CL2008002798A patent/CL2008002798A1/es unknown
- 2008-09-18 MX MX2010003060A patent/MX2010003060A/es active IP Right Grant
- 2008-09-18 DE DE602008005784T patent/DE602008005784D1/de active Active
- 2008-09-18 EP EP08804373A patent/EP2203440B1/en active Active
- 2008-09-18 HR HR20110394T patent/HRP20110394T1/hr unknown
- 2008-09-18 CA CA2699849A patent/CA2699849C/en active Active
- 2008-09-18 RU RU2010115765/04A patent/RU2477724C2/ru active
- 2008-09-18 US US12/678,961 patent/US9573933B2/en not_active Expired - Fee Related
- 2008-09-18 ES ES08804373T patent/ES2363838T3/es active Active
- 2008-09-18 JP JP2010525346A patent/JP5438007B2/ja not_active Expired - Fee Related
- 2008-09-18 AT AT08804373T patent/ATE502934T1/de not_active IP Right Cessation
- 2008-09-18 DK DK08804373.2T patent/DK2203440T3/da active
- 2008-09-18 SI SI200830267T patent/SI2203440T1/sl unknown
- 2008-09-18 CN CN200880117463A patent/CN101868453A/zh active Pending
- 2008-09-18 BR BRPI0817223A patent/BRPI0817223B8/pt not_active IP Right Cessation
- 2008-09-18 AU AU2008300527A patent/AU2008300527B2/en not_active Ceased
- 2008-09-18 WO PCT/EP2008/062433 patent/WO2009037308A1/en not_active Ceased
- 2008-09-18 CN CN201510083830.XA patent/CN104761541A/zh active Pending
- 2008-09-19 UY UY31349A patent/UY31349A1/es unknown
- 2008-09-19 PE PE2008001643A patent/PE20090817A1/es not_active Application Discontinuation
- 2008-09-19 PA PA20088796901A patent/PA8796901A1/es unknown
- 2008-09-19 TW TW097135916A patent/TWI434841B/zh not_active IP Right Cessation
- 2008-09-19 AR ARP080104085A patent/AR068627A1/es unknown
2017
- 2017-01-04 US US15/398,291 patent/US20170112818A1/en not_active Abandoned
2018
- 2018-05-17 US US15/982,043 patent/US20180263966A1/en not_active Abandoned
2019
- 2019-12-18 US US16/718,955 patent/US11583524B2/en active Active

Also Published As

Publication number	Publication date
BRPI0817223B1 (pt)	2020-04-07
CL2008002798A1 (es)	2009-06-05
SI2203440T1 (sl)	2011-07-29
EP2203440B1 (en)	2011-03-23
RU2010115765A (ru)	2011-10-27
AU2008300527A1 (en)	2009-03-26
JP5438007B2 (ja)	2014-03-12
AU2008300527B2 (en)	2013-08-29
EP2203440A1 (en)	2010-07-07
US9573933B2 (en)	2017-02-21
ATE502934T1 (de)	2011-04-15
US20200121667A1 (en)	2020-04-23
CN101868453A (zh)	2010-10-20
WO2009037308A1 (en)	2009-03-26
RU2477724C2 (ru)	2013-03-20
HRP20110394T1 (hr)	2011-06-30
ES2363838T3 (es)	2011-08-17
UY31349A1 (es)	2009-03-31
BRPI0817223B8 (pt)	2021-05-25
TWI434841B (zh)	2014-04-21
PA8796901A1 (es)	2009-05-15
CN104761541A (zh)	2015-07-08
CA2699849A1 (en)	2009-03-26
JO2704B1 (en)	2013-03-03
MX2010003060A (es)	2010-04-07
TW200930709A (en)	2009-07-16
AR068627A1 (es)	2009-11-25
DE602008005784D1 (de)	2011-05-05
US11583524B2 (en)	2023-02-21
PE20090817A1 (es)	2009-07-02
JP2010539220A (ja)	2010-12-16
US20180263966A1 (en)	2018-09-20
CA2699849C (en)	2015-10-27
US20100240637A1 (en)	2010-09-23
US20170112818A1 (en)	2017-04-27
DK2203440T3 (da)	2011-06-20

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-15	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-02-04	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-04-07	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-07-09	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-10-22	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2792 DE 09-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
NO2020028I1 (no)	2020-08-12	saksagliptin og dapagliflozin
DK3345625T3 (da)	2021-02-01	Farmaceutisk sammensætning og indgivelser deraf
DK2220320T3 (da)	2019-11-04	Forseglet enhed og mellemstykke
DK2203440T3 (da)	2011-06-20	Inhibitorer af interaktionen mellem MDM2 og P53
DK2170827T3 (da)	2013-11-18	Indolin-2-oner og aza-indolin-2-oner
DK2185164T3 (da)	2017-11-13	Sammensætning og terapeutisk antitumorvaccine
DK2254873T3 (da)	2014-06-30	Benzodiazepinforbindelse og farmaceutisk sammensætning.
EP1995290A4 (en)	2011-03-02	PRESSURE-SENSITIVE ADHESIVE COMPOSITION AND PRESSURE-SENSITIVE ADHESIVE SHEET USING THE SAME
DE602007012419D1 (de)	2011-03-24	Hochfestes haftpolymergel und klebeband
DK2207773T3 (da)	2012-09-10	Heterocyklisk forbindelse og farmaceutisk sammensætning deraf.
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
EP2021283A4 (en)	2010-07-07	MECHANICAL REVERSIBLE GEL
DK2158199T3 (da)	2011-02-07	Piperidinforbindelser og anvendelser deraf
EP1841794A4 (en)	2008-10-29	MODULATORS ADAM-9
DK2292592T3 (da)	2012-10-08	Sulfonamidforbindelse og anvendelse deraf
BRPI0815203A2 (pt)	2017-03-28	gel contendo pirfenidona
EP2121896A4 (en)	2013-11-13	Torsionally flexible sealed drive
BRPI0809684A2 (pt)	2014-10-07	Embalagem, e embalagem
DK2152699T3 (da)	2011-04-18	Quinolon-forbindelse og farmaceutisk sammensætning
FI20055630A0 (fi)	2005-11-30	Kasvonaamio
DK2334596T3 (da)	2012-09-24	Ferriphosphatbaseret sammensætning og anvendelse heraf
ATE527249T1 (de)	2011-10-15	Indole
EP1915162A4 (en)	2009-08-26	Modulators
EP2135915A4 (en)	2011-07-06	FLUORESCENT FILM
DE602007007247D1 (de)	2010-07-29	Asphaltzusammensetzung und klebfolie